In a move aimed at deepening the role of artificial intelligence in pharmaceutical manufacturing, technology company Aizon and engineering consultancy Sequence have announced a new strategic partnership.
The collaboration will see the integration of Aizon’s AI-powered analytics platform with Sequence’s expertise in compliance and facility engineering. The companies say the joint effort is intended to support faster digital transformation across pharmaceutical manufacturing environments, particularly those governed by strict regulatory requirements.
Sequence, founded in 2002 and based in Raleigh, North Carolina, has a long-standing presence in pharmaceutical consulting, offering services that range from engineering support to compliance strategy. Aizon, for its part, provides AI-driven solutions for process optimization and quality control within drug manufacturing operations.
The partnership will focus on four key areas:
- Digitalization of Manufacturing: The companies aim to help clients fully digitize manufacturing operations within a six-week timeframe, emphasizing reduced disruption and faster access to real-time data.
- Faster Facility Startup and Validation: By applying AI to commissioning, qualification, and validation (CQV) processes, the collaboration is expected to reduce the time and complexity involved in launching new production facilities.
- Process Optimization: Combining predictive analytics with engineering knowledge, the firms plan to enable continuous monitoring and performance improvements in manufacturing lines, targeting higher yield and lower variability.
- Data-Driven Decision Making: The partnership will provide tools and frameworks to support operational decisions using insights derived from manufacturing data.
Leaders from both organizations highlighted the potential benefits to the broader pharmaceutical industry. Pep Gubau, Aizon’s CEO, said the initiative aims to accelerate innovation and improve access to life-saving therapies. Justin Wood, Chief Services Officer at Sequence, echoed that sentiment, noting the effort is designed to help manufacturers streamline operations and reduce time to market.